Mallinckrodt plc

Mallinckrodt plc Acción · IE00BBGT3753 (OTC) — cotizaciones en tiempo real, datos de la empresa, dividendos, fundamentales y análisis de cartera con IA en MoneyPeak

Resumen
Análisis impulsado por IA
Análisis fundamental
Descubre lo que realmente dicen los números — antes que el mercado
Analizar ahora
Sentimiento de noticias
¿Las noticias de hoy son una señal de compra o una alerta?
Analizar ahora
Comprar / Mantener / Vender
¿Comprar, mantener o vender? Obtén el veredicto de la IA ahora.
Analizar ahora
Evaluación de riesgos
Descubre riesgos ocultos antes de que afecten a tu cartera.
Analizar ahora
Valor justo
¿Esta acción está barata, correctamente valorada o sobrevalorada?
Analizar ahora
Últimos análisis de IA sobre Mallinckrodt plc
Sin cotización
Perfil de la empresa para Mallinckrodt plc Acción
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Datos de la empresa

Nombre Mallinckrodt plc
Empresa Mallinckrodt plc
Sitio web https://www.mallinckrodt.com
Mercado principal OTC UTC
ISIN IE00BBGT3753
Tipo de valor Acción
Sector Healthcare
Industria Drug Manufacturers - Specialty & Generic
CEO Mark Christopher Trudeau
País Irlanda
Moneda USD
Empleados 2,8 T
Dirección College Business & Technology Park, 15 Dublin
Fecha de OPV 2013-06-17

Símbolos de cotización

Nombre Símbolo
Over The Counter MNKKQ
Otras acciones
Los inversores que tienen Mallinckrodt plc también tienen las siguientes acciones en su cartera:
CGN Power Co., Ltd.
CGN Power Co., Ltd. Acción
GOLDMAN SACHS GROUP SECURITIES STRATS TRUST FOR GOLDMAN SACHS GROUP SECURITIES, SERIES 2006-2
GOLDMAN SACHS GROUP SECURITIES STRATS TRUST FOR GOLDMAN SACHS GROUP SECURITIES, SERIES 2006-2 Fondo